Subsequent Event (Details Narrative) - USD ($) |
3 Months Ended | |||
|---|---|---|---|---|
May 14, 2020 |
May 01, 2020 |
Mar. 31, 2020 |
May 15, 2020 |
|
| Warrant prior exercised shares | 38,000 | |||
| Warrants outstanding | 26,538,593 | |||
| Subsequent Event [Member] | Series 1 Warrants [Member] | ||||
| Warrant exercise price | $ 0.75 | |||
| Shares attributable to short term of warrants | 9,545,334 | 9,583,334 | ||
| Warrant description | The earlier of on the earlier of (1) the eighteen-month anniversary of the date of issuance and (2) twenty-one trading days following our release of top-line data related to its Phase 2 double blind, placebo controlled clinical trial of AG013. On April 15, 2020, the Company announced top-line data thereby triggering the earlier expiration of the warrants to May 14, 2020. | |||
| Warrant prior exercised shares | 38,000 | |||
| Warrants outstanding | 26,155,259 | |||
| Subsequent Event [Member] | Stock Purchase Agreement [Member] | Mr. Hernandez [Member] | ||||
| Acquired percentage | 100.00% | |||
| Cash consideration | $ 1,925,000 | |||
| Pre-Transaction liabilities | $ 500,000 | |||
| Number of restricted shares | 9,200,000 | |||
| Share price per share | $ 2.50 | |||
| Number of shares warrant purchase | 9,200,000 | |||
| Warrant exercise price | $ 1.25 | |||
| Contingent consideration description | The above consideration, Mr. Hernandez is entitled to receive contingent consideration based upon the exercise of certain of the Company's outstanding warrants as follows: (i) twenty percent (20%) of the cash proceeds received by the Company upon exercise of the Company's warrants carrying an exercise price of $0.75 and $0.90 and (ii) forty-five percent (45%) of the cash proceeds received by the Company upon exercise of the Company's warrants carrying an exercise price of $1.00, in each case, for so long as the warrants remain outstanding. |